Having stabilized following a severe downturn last summer, Viking Therapeutics has announced the completion of patient enrollment for a key clinical trial. This technical achievement marks a ...
The choice isn't that hard.
Eli Lilly is getting its hands on a promising pipeline candidate thanks to an acquisition. The stock may not gain much more ...
Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive ...
Investor's Business Daily on MSN
Why Eli Lilly is the IBD stock of the day — again — as its Novo Nordisk rivalry deepens
Eli Lilly is Wednesday's IBD Stock Of The Day. Lilly shares are bounding off their 50-day line with a new buying opportunity ...
Novo Nordisk A/S is rated a buy, driven by FDA approval of its oral Wegovy, strong fundamentals, and attractive valuation versus Eli Lilly. Recent clinical data and first-mover advantage position ...
On the Jan. 5, 2026, episode of The Morning Filter podcast, Morningstar Chief US Market Strategist Dave Sekera commented on what the Food and Drug Administration’s approval of Novo Nordisk’s NVO ...
Zacks Investment Research on MSN
Eli Lilly (LLY) stock sinks as market gains: What you should know
In the latest trading session, Eli Lilly (LLY) closed at $1,064.29, marking a -2.12% move from the previous day. This change ...
The company has seen revenue soar in recent quarters thanks to its weight loss portfolio. Eli Lilly (NYSE: LLY) is close to doing something no other pharmaceutical company has ever done: reaching $1 ...
Shares of Eli Lilly & Co. LLY slipped 1.99% to $1,063.56 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.65% to 6,966.28 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results